World Health Organization Recognizes MediPines AGM100® in 2021 Compendium for Innovative Health Technologies

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

World Health Organization Recognizes MediPines AGM100® in 2021 Compendium for Innovative Health Technologies

Canada NewsWire

ORANGE COUNTY, Calif., Sept. 21, 2021 /CNW/ -- The World Health Organization (WHO) has just featured  MediPines AGM100®, pulmonary gas exchange analyzer as an innovative technology in their 2021 compendium, "WHO compendium of innovative health technologies for low-resource settings". This year's annual assessment report provided much needed global awareness for technologies that could have an immediate impact on COVID-19 and other general health outcomes. The portable MediPines AGM100 was selected for its ability to "instantly detect changes in pulmonary gas exchange in disease states such as COPD, pneumonia, influenza, and ARDS caused by COVID-19", as reported in the WHO assessment.  

The AGM100 provides clinicians with a full picture of patient blood oxygen and gas exchange levels right at the bedside without requiring any blood draws or needle sticks, which helps prevent problems like infection in low resource settings. This provides substantial improvements in patient safety and care, since clinicians can objectively understand what's exactly happening in the lungs and blood without any time delays or logistical complications.

The WHO compendium report's purpose is to acknowledge new medical technologies with significant global potential and to bring awareness for better implementation and uptake, especially in low resource settings. The WHO panel of international experts participated in the selection and evaluation project, including influential physicians, biomedical engineers, and regulatory experts from 37 countries.   In the end, they selected the top 24 technologies out of hundreds considered; MediPines is one of only 15 highlighted technologies which is available commercially.

"Our product has proven very beneficial in the assessment of COVID-19 patients," said Steve Lee, MediPines CEO and co-inventor of the AGM100.  "We are honored to be recognized by the World Health Organization. MediPines remains committed to working hand-in-hand with healthcare professionals and policy makers seeking to combat COVID-19 and other deadly respiratory diseases."

MediPines AGM100®

MediPines AGM100 is the world's first non-invasive gas exchange analyzer. It is a respiratory monitoring system used to rapidly assess a patient's respiratory status.  The device is FDA cleared and approved by Health Canada for COVID-19 Emergency Use.  

About MediPines

MediPines Corporation, based in California, is a market leader in respiratory assessment and monitoring of pulmonary gas exchange. The company mission is to advance respiratory medicine by providing physiology-based respiratory devices that enhance clinical effectiveness and achieve better patient outcomes.

Luan Price
[email protected]  

Cision View original content to download multimedia:

SOURCE MediPines

Cision View original content to download multimedia:

Copyright CNW Group 2021

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).